Financials HitGen Inc.

Equities

688222

CNE1000040G3

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 05/05/2024 BST			5-day change	1st Jan Change
13.79 ^CNY	+2.00%		+3.30%	-8.01%

04-24	HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-23	HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Valuation

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Capitalization ¹	12,068	9,412	5,401	5,508	5,508	-
Enterprise Value (EV) ¹	12,068	9,412	5,401	5,988	5,508	5,508
P/E ratio	177 x	147 x	225 x	136 x	109 x	89.9 x
Yield	-	-	-	0.33%	0.07%	0.07%
Capitalization / Revenue	49.5 x	30.3 x	16.4 x	16.1 x	12.6 x	10.9 x
EV / Revenue	49.5 x	30.3 x	16.4 x	16.1 x	12.6 x	10.9 x
EV / EBITDA	142 x	102 x	92 x	76.9 x	81.4 x	71.2 x
EV / FCF	-149 x	-97.7 x	-157 x	83.3 x	239 x	131 x
FCF Yield	-0.67%	-1.02%	-0.64%	1.2%	0.42%	0.76%
Price to Book	9.44 x	7.15 x	4.15 x	4.42 x	3.94 x	3.78 x
Nbr of stocks (in thousands)	400,680	400,680	400,680	399,441	399,441	-
Reference price ²	30.12	23.49	13.48	13.79	13.79	13.79
Announcement Date	26/02/21	25/02/22	27/02/23	23/02/24	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Net sales ¹	243.6	311.1	329.6	371.7	436	504.5
EBITDA ¹	85.05	92.59	58.69	77.88	67.67	77.33
EBIT ¹	59.57	45.76	12.12	35.14	41	49.67
Operating Margin	24.46%	14.71%	3.68%	9.46%	9.4%	9.84%
Earnings before Tax (EBT) ¹	63.36	55.83	12.44	38.83	42.67	51.33
Net income ¹	64.02	63.38	25.27	43.94	50.7	61.08
Net margin	26.28%	20.38%	7.66%	11.82%	11.63%	12.11%
EPS ²	0.1700	0.1600	0.0600	0.1100	0.1267	0.1533
Free Cash Flow ¹	-81.13	-96.33	-34.46	71.91	23	42
FCF margin	-33.31%	-30.97%	-10.45%	19.35%	5.28%	8.32%
FCF Conversion (EBITDA)	-	-	-	92.33%	33.99%	54.31%
FCF Conversion (Net income)	-	-	-	163.63%	45.37%	68.76%
Dividend per Share ²	-	-	-	0.0500	0.0100	0.0100
Announcement Date	26/02/21	25/02/22	27/02/23	23/02/24	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period:

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Net Debt	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-
Free Cash Flow ¹	-81.1	-96.3	-34.5	71.9	23	42
ROE (net income / shareholders' equity)	6.26%	4.89%	1.91%	3.3%	3.59%	4.2%
ROA (Net income/ Total Assets)	5.61%	3.78%	1.49%	2.58%	2.91%	3.35%
Assets ¹	1,142	1,676	1,691	1,700	1,745	1,823
Book Value Per Share ²	3.190	3.280	3.250	3.390	3.500	3.650
Cash Flow per Share ²	0	0.1100	0.1300	0.3100	0.1600	0.1800
Capex ¹	82.7	140	87.2	53.3	35	32
Capex / Sales	33.96%	44.95%	26.45%	14.34%	8.03%	6.34%
Announcement Date	26/02/21	25/02/22	27/02/23	23/02/24	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for HitGen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.79 CNY

Average target price

16 CNY

Spread / Average Target

+16.03%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HITGEN INC.	-8.01%	764M
REGENERON PHARMACEUTICALS, INC.	+9.15%	106B
VERTEX PHARMACEUTICALS INCORPORATED	-1.08%	104B
ARGENX SE	+7.02%	23.25B
BIONTECH SE	-11.55%	22.5B
GENMAB A/S	-7.38%	18.7B
WUXI APPTEC CO., LTD.	-37.08%	17.95B
BEIGENE, LTD.	-9.91%	16.99B
NEUROCRINE BIOSCIENCES, INC.	+7.55%	14.26B
SAREPTA THERAPEUTICS, INC.	+40.04%	12.76B

Bio Therapeutic Drugs